Assembly Biosciences Inc. (ASMB)
14.60
-0.29 (-1.95%)
At close: Jan 14, 2025, 3:59 PM
14.74
0.95%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 13.5 |
| Market Cap | 92.81M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.89 |
| PE Ratio (ttm) | -2.12 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 16 |
| Volume | 24,764 |
| Avg. Volume (20D) | 33,581 |
| Open | 15.33 |
| Previous Close | 14.89 |
| Day's Range | 14.24 - 15.73 |
| 52-Week Range | 9.12 - 19.93 |
| Beta | undefined |
About ASMB
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical tri...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 17, 2010
Employees 65
Stock Exchange NASDAQ
Ticker Symbol ASMB
Website https://www.assemblybio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ASMB stock is "Hold." The 12-month stock price forecast is $35, which is an increase of 139.72% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Assembly Biosciences Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of $7.05M, reflecting a -1.58% YoY shrinking and earnings per share of -1.75, making a 0.57% increase YoY.
Analysts project revenue of $7.05M, reflecting a -1.58% YoY shrinking and earnings per share of -1.75, making a 0.57% increase YoY.
